B cell-based vaccine transduced with esat6-expressing vaccinia virus and presenting α-galactosylceramide is a novel vaccine candidate against esat6-expressing mycobacterial diseases

Bo Eun Kwon, Jae Hee Ahn, Eun Kyoung Park, Hyunjin Jeong, Hyo Ji Lee, Yu Jin Jung, Sung Jae Shin, Hye Sook Jeong, Jung Sik Yoo, Eunkyoung Shin, Sang Gu Yeo, Sun Young Chang, Hyun Jeong Ko

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in Mycobacterium tuberculosis as well as in some non-tuberculous mycobacteria (NTM), such as M. kansasii. M. kansasii is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, which is clinically indistinguishable from tuberculosis. In the current study, we designed a novel cell-based vaccine using B cells that were transduced with vaccinia virus expressing ESAT6 (vacESAT6), and presenting α-galactosylceramide (αGC), a ligand of invariant NKT cells. We found that B cells loaded with αGC had increased levels of CD80 and CD86 after in vitro stimulation with NKT cells. Immunization of mice with B/αGC/vacESAT6 induced CD4+ T cells producing TNF-α and IFN-γ in response to heat-killed M. tuberculosis. Immunization of mice with B/αGC/vacESAT6 ameliorated severe lung inflammation caused by M. kansasii infection. We also confirmed that immunization with B/αGC/vacESAT6 reduced M. kansasii bacterial burden in the lungs. In addition, therapeutic administration of B/αGC/vacESAT6 increased IFN-γ+ CD4+ T cells and inhibited the progression of lung pathology caused by M. kansasii infection. Thus, B/αGC/vacESAT6 could be a potent vaccine candidate for the prevention and treatment of ESAT6-expressing mycobacterial infection caused by M. kansasii.

Original languageEnglish
Article number2542
JournalFrontiers in Immunology
Volume10
Issue numberOCT
DOIs
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'B cell-based vaccine transduced with esat6-expressing vaccinia virus and presenting α-galactosylceramide is a novel vaccine candidate against esat6-expressing mycobacterial diseases'. Together they form a unique fingerprint.

  • Cite this

    Kwon, B. E., Ahn, J. H., Park, E. K., Jeong, H., Lee, H. J., Jung, Y. J., Shin, S. J., Jeong, H. S., Yoo, J. S., Shin, E., Yeo, S. G., Chang, S. Y., & Ko, H. J. (2019). B cell-based vaccine transduced with esat6-expressing vaccinia virus and presenting α-galactosylceramide is a novel vaccine candidate against esat6-expressing mycobacterial diseases. Frontiers in Immunology, 10(OCT), [2542]. https://doi.org/10.3389/fimmu.2019.02542